|
|
|
|
| LEADER |
01503nam a2200277 u 4500 |
| 001 |
EB002001867 |
| 003 |
EBX01000000000000001164768 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited)
|h Elektronische Ressource
|b indication : giant cell arteritis
|
| 246 |
3 |
1 |
|a Tocilizumab (Actemra - Hoffmann-La Roche Limited)
|
| 250 |
|
|
|a Final
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c March 29, 2018, 2018
|
| 300 |
|
|
|a 1 PDF file (7 pages)
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK533005
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that tocilizumab be reimbursed for the treatment of giant cell arteritis (GCA) in adult patients, if the following criteria and conditions are met. At initiation of therapy, or with relapse, patients should be receiving prednisone. Duration of therapy with tocilizumab should be limited to 52 weeks per treatment course. Patients should be under the care of a physician with experience in the diagnosis and management of GCA. A reduction in price
|